How Europe Can Compete in the Global Biotech Race: Lessons from the Capital for Cures Event Series
If biotech were a footrace, Europe would be the competitor with flawless running shoes, world-class muscle tone—and one leg
The Mansion House Accord: Reinvigorating UK Investment or Merely Rebadging the Status Quo?
In July 2023, the United Kingdom government launched the Mansion House Compact, a voluntary commitment by nine of the country’
Whither ESG? The Curious Case of Pharma's Forgotten Acronym
Ah, ESG! Not long ago, you could hardly sip your oat milk latte—or endure a quarterly earnings call—without
Health Economics: Pharma’s Favorite Crystal Ball
Health economics is to pharma what a crystal ball is to a fortune teller—draped in mystique, full of promise,
ICER: The Gatekeeper of European Healthcare, or a Flawed Oracle?
The Incremental Cost-Effectiveness Ratio (ICER) is the darling of health economists and the bane of pharmaceutical companies. At its heart,
In a Hole in the Budget There Lived a KOL
Not a nasty, dirty, wet hole, nor yet a humble one. This was a suite at the Four Seasons, with
The Problem with Markov Models
Markov models have become a default tool in drug development, used for modeling disease progression, treatment outcomes, and cost-effectiveness. While
AI in Biotech: Taking Stock of a Decade of Progress and the Challenges Ahead
Artificial intelligence has had a profound decade in biotech, advancing from a promising academic endeavor to a critical driver of
The Problem with Optimism Bias in Biotech Projections: A Quantitative and Probabilistic Analysis
Optimism bias, the cognitive tendency to overestimate the likelihood of favorable outcomes and underestimate risks, is a pervasive issue in
The Problem with Biotech’s Love Affair with Academia
Biotech and academia are the original odd couple. One is driven by bold bets on untested science and the hope
